


Express Mail Label No.: EL862126348US

Date of Deposit: August 30, 2001

Attorney Docket No. 15966-620 (CURA-120)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5
RECEIVED

SEP 05 2001

TECH CENTER 1600/2900

APPLICANTS:

Spaderna *et al*

ASSIGNEE:

CuraGen Corporation

SERIAL NUMBER:

09/735,981

EXAMINER:

Not Yet Assigned

FILING DATE:

December 13, 2000

ART UNIT:

1653

FOR:

POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

Box IDS

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement (2 pages);
- ☒ Modified Form 1449/PTO (2 pages) in duplicate;
- ☒ Copies of Cited references; B1-B4, C1-C14; and
- ☒ Return Postcard.

No fee is believed to be due at this time. However, the Commissioner is hereby authorized to charge any additional fees that may be due to Deposit Account No. 50-0311, Reference No. 15966-620 (CURA-120). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Cynthia A. Kozakiewicz, Reg. No. 42,764

Attorneys for Applicant

MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

DATE: August 30, 2001

Express Mail Label No.: EL862126348US

Date of Deposit: August 30, 2001

Attorney Docket No. 15966-620 (Cura-120)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Spaderna *et al.*

SERIAL NUMBER: 09/735,981

EXAMINER: Not Yet Assigned

FILING DATE: December 13, 2000

ART UNIT: 1653

FOR: POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

BOX IDS

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT


Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application.
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application.
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.



TECH CENTER 1600/2900

SEP 05 2001

RECEIVED

APPLICANTS: Spaderna *et al.*
U.S.S.N.: 09/735,981

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 15966-620 (CURA-20)

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: August 30, 2001


Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<div>Modified Form 1449/PTO</div> <div></div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>	Application Number	09/735,981
	Filing Date	12/13/00
	First Named Inventor	Spaderna
	Group Art Unit	1653
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	15966-620

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1						

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No
	B1	WO 96/01640	Michigan Cancer Foundation	Jan. 25, 1995		
	B2	WO 97/27747	Human Genome Sciences	Aug. 7, 1997		
	B3	WO 97/35028	Human Genome Sciences	Sep. 25, 1997		
	B4	WO 99/43696	AXYS Pharmaceuticals, Inc.	Sep. 2, 1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Adamson, P. B., E. Vanoli, et al. (1998). "Antifibrillatory efficacy of ersentilide, a novel beta-adrenergic and lkr blocker, in conscious dogs with a healed myocardial infarction." <i>Cardiovasc Res</i> 40(1): 56-63.
	C2	Doherty, et al., 1995 "Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein Phosphatase-1." <i>FEBS Lett.</i> 375 (3): 294-298. GenBank Accession Number: Y18208
	C3	Doherty, et al., 1995 "Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein Phosphatase-1." <i>FEBS Lett.</i> 375 (3): 294-298. GenBank Accession Number: Q63759
	C4	Doherty, M. J., J. Cadefau, et al. (1998). "Loss of the hepatic glycogen-binding subunit (GL) of protein phosphatase 1 underlies deficient glycogen synthesis in insulin- dependent diabetic rats and in adrenalectomized starved rats." <i>Biochem J</i> 333(Pt 2): 253-7.
	C5	Lamerdin, et al., 1998 "Sequence analysis of a 3.5 Mb contig in human 19p13.3 containing a serine protease gene cluster." Direct Submission. GenBank Accession Number: AC004528
	C6	Lamerdin, et al., 1998 Direct Submission. GenBank Accession Number: O60391
	C7	Lin, et al., 1996 "Cloning of the cDNA for the human NMDA receptor NR2C subunit and its expression in the central nervous system and periphery." <i>Bran Res. Mol. Brain Res.</i> 43 (1-2): 57-64. GenBank Accession Number: Q14957
	C8	Lloyd, D. 1999 Direct Submission. GenBank Accession Number: HS1163J1 (AL031588)
	C9	Morris, G. F., R. Bullock, et al. (1999). "Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators." <i>J Neurosurg</i> 91(5): 737-43.
	C10	Muller, G. (2000). "Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach." <i>Curr Med Chem</i> 7(9): 861-88.
	C11	Nair, L. A. and A. O. Grant (1997). "Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential." <i>Cardiovasc Drugs Ther</i> 11(2): 149-67.
	C12	Newman, T. 1998 Direct Submission. GenBank Accession Number: T14119
	C13	Noorbala, et al., 1999 "Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia." <i>J Clin Pharm Ther</i> 24(5): 369-74.
	C14	van Neuren, A. S., G. Muller, et al. (1999). "Molecular modelling studies on G protein-coupled receptors: from sequence to structure?" <i>J Recept Signal Transduct Res</i> 19(1-4): 341-53.

TECH CENTER 1600/2900

SEP 05 2001

Express Mail No. EL862126348
Date of Deposit: August 30, 2001


Page 2 of 2
Attorney Docket No. 15966-690 (CURA-120)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



TRA 1560916v1